| pubmed-article:16476834 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16476834 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:16476834 | lifeskim:mentions | umls-concept:C0024623 | lld:lifeskim |
| pubmed-article:16476834 | lifeskim:mentions | umls-concept:C0032790 | lld:lifeskim |
| pubmed-article:16476834 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:16476834 | pubmed:dateCreated | 2006-2-14 | lld:pubmed |
| pubmed-article:16476834 | pubmed:abstractText | Adjuvant chemotherapy for gastric cancer after potentially curative surgery has been under clinical investigation for more than four decades. However, potentially curative resection can be performed in only 30%-50% of patients. The objective of this article is to review briefly the clinical trials available in the current literature using adjuvant cytotoxic chemotherapy in patients with gastric cancer after potentially curative surgical resection. | lld:pubmed |
| pubmed-article:16476834 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16476834 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16476834 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16476834 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16476834 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16476834 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16476834 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16476834 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:16476834 | pubmed:issn | 1083-7159 | lld:pubmed |
| pubmed-article:16476834 | pubmed:author | pubmed-author:RadererMarkus... | lld:pubmed |
| pubmed-article:16476834 | pubmed:author | pubmed-author:SchmidingerMa... | lld:pubmed |
| pubmed-article:16476834 | pubmed:author | pubmed-author:WöhrerStefanS | lld:pubmed |
| pubmed-article:16476834 | pubmed:author | pubmed-author:HejnaMichaelM | lld:pubmed |
| pubmed-article:16476834 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16476834 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:16476834 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16476834 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16476834 | pubmed:pagination | 136-45 | lld:pubmed |
| pubmed-article:16476834 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:16476834 | pubmed:meshHeading | pubmed-meshheading:16476834... | lld:pubmed |
| pubmed-article:16476834 | pubmed:meshHeading | pubmed-meshheading:16476834... | lld:pubmed |
| pubmed-article:16476834 | pubmed:meshHeading | pubmed-meshheading:16476834... | lld:pubmed |
| pubmed-article:16476834 | pubmed:meshHeading | pubmed-meshheading:16476834... | lld:pubmed |
| pubmed-article:16476834 | pubmed:meshHeading | pubmed-meshheading:16476834... | lld:pubmed |
| pubmed-article:16476834 | pubmed:meshHeading | pubmed-meshheading:16476834... | lld:pubmed |
| pubmed-article:16476834 | pubmed:meshHeading | pubmed-meshheading:16476834... | lld:pubmed |
| pubmed-article:16476834 | pubmed:meshHeading | pubmed-meshheading:16476834... | lld:pubmed |
| pubmed-article:16476834 | pubmed:meshHeading | pubmed-meshheading:16476834... | lld:pubmed |
| pubmed-article:16476834 | pubmed:meshHeading | pubmed-meshheading:16476834... | lld:pubmed |
| pubmed-article:16476834 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16476834 | pubmed:articleTitle | Postoperative chemotherapy for gastric cancer. | lld:pubmed |
| pubmed-article:16476834 | pubmed:affiliation | Department of Internal Medicine I, Division of Oncology, University of Vienna, Austria. michael.hejna@meduniwien.ac.at | lld:pubmed |
| pubmed-article:16476834 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16476834 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16476834 | lld:pubmed |
